enGene Holdings Inc. (NASDAQ:ENGN) Major Shareholder Acquires $2,164,044.88 in Stock

enGene Holdings Inc. (NASDAQ:ENGN) major shareholder Growth Opportunities F. Forbion bought 341,332 shares of enGene stock in a transaction on Monday, September 30th. The shares were bought at an average price of $6.34 per share, for a total transaction of $2,164,044.88. Following the acquisition, the insider now owns 2,400,791 shares of the company’s stock, valued at approximately $15,221,014.94. The trade was a 0.00 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

enGene Price Performance

NASDAQ ENGN opened at $9.02 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 19.52 and a current ratio of 19.52. enGene Holdings Inc. has a 52-week low of $4.42 and a 52-week high of $43.00. The business has a 50 day simple moving average of $6.71 and a 200 day simple moving average of $9.78. The stock has a market cap of $398.38 million, a price-to-earnings ratio of -5.24 and a beta of -0.69.

enGene (NASDAQ:ENGN) last issued its quarterly earnings data on Tuesday, September 10th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.05. Analysts anticipate that enGene Holdings Inc. will post -1.56 earnings per share for the current fiscal year.

Institutional Trading of enGene

Hedge funds and other institutional investors have recently modified their holdings of the company. Logos Global Management LP boosted its position in shares of enGene by 50.0% during the second quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock worth $11,316,000 after buying an additional 400,000 shares during the period. SR One Capital Management LP bought a new stake in enGene in the 2nd quarter valued at approximately $4,715,000. Janus Henderson Group PLC acquired a new position in enGene during the 1st quarter worth approximately $17,095,000. Finally, Altitude Crest Partners Inc. bought a new position in shares of enGene during the 1st quarter worth approximately $2,039,000. Institutional investors and hedge funds own 64.16% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently weighed in on ENGN shares. Morgan Stanley reiterated an “overweight” rating and issued a $40.00 price target on shares of enGene in a research report on Wednesday, September 11th. Oppenheimer reissued an “outperform” rating and set a $30.00 price target on shares of enGene in a research report on Tuesday, September 24th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $33.67.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.